Cargando…

Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI

BACKGROUND: There is a paucity of real-world data regarding the clinical impact of dual antiplatelet therapy (DAPT) interruption (temporary or permanent) among patients at high ischemic risk. The aim of this study was to assess the risk of cardiovascular events after interruption of DAPT in high-ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hao-Yu, Xu, Bo, Song, Chen-Xi, Guan, Chang-Dong, Xie, Li-Hua, Zhao, Yan-Yan, Cai, Zhong-Xing, Yuan, Sheng, Dou, Ke-Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776446/ https://www.ncbi.nlm.nih.gov/pubmed/35095347 http://dx.doi.org/10.1155/2022/3895205

Ejemplares similares

Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients
por: Wang, Hao-Yu, et al.
Publicado: (2022)

One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
por: Pivato, Carlo A., et al.
Publicado: (2022)

The stent in the high-bleeding risk patient: antiplatelet monotherapy?
por: Capranzano, Piera
Publicado: (2022)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

Correction to: One‐Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus‐Eluting Stents in High Bleeding Risk Patients
Publicado: (2022)

Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
por: Jeger, Raban V., et al.
Publicado: (2019)

Impact of early (3 months) dual antiplatelet treatment interruption prior to renal transplantation in patients with second-generation DES on perioperative stent thrombosis and MACEs
por: Doğan, Ali, et al.
Publicado: (2017)

Balancing Between Ischemic and Bleeding Risk in PCI Patients With ‘Bi-Risk’
por: Park, Mahn-Won
Publicado: (2022)

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI
por: Türker, Yasin
Publicado: (2016)

Non-inferiority of 1 month versus longer dual antiplatelet therapy in patients undergoing PCI with drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials
por: Bajraktari, Gani, et al.
Publicado: (2022)

PCI compliance : the definitive guide
por: Bhargav, Abhay
Publicado: (2014)

Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries
por: Kronlage, Mariya, et al.
Publicado: (2017)

Dual Antiplatelet Therapy Over 6 Months Increases the Risk of Bleeding after Biodegradable Polymer-Coated Sirolimus Eluting Stents Implantation: Insights from the CREATE Study
por: ZHANG, LEI, et al.
Publicado: (2014)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
por: Tsigkas, Grigorios, et al.
Publicado: (2023)

Should antiplatelet therapy be interrupted in drug eluting stent recipients throughout the periendoscopic period? A very late stent thrombosis case report and review of the literature
por: Dong, Peng, et al.
Publicado: (2014)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)

Short Versus Long-Term Dual Antiplatelet Therapy in Patients at High Bleeding Risk Undergoing PCI in Contemporary Practice: A Systemic Review and Meta-analysis
por: Mankerious, Nader, et al.
Publicado: (2023)

Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation
por: Voudris, Vassilis, et al.
Publicado: (2014)

Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI
por: Wang, Hao-Yu, et al.
Publicado: (2020)

Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI
por: Schäfer, Andreas, et al.
Publicado: (2020)

Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis
por: Lin, Chun-Jen, et al.
Publicado: (2022)

Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI
por: Yamamoto, Ko, et al.
Publicado: (2023)

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
por: Guo, Yong-zhe, et al.
Publicado: (2021)

Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy
por: Egholm, Gro, et al.
Publicado: (2016)

Dual-Antiplatelet Therapy May Not Be Associated With an Increased Risk of In-hospital Bleeding in Patients With Moderate or Severe Ischemic Stroke
por: Khazaal, Ossama, et al.
Publicado: (2021)

Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
por: Yoon, Gwang-Seok, et al.
Publicado: (2021)

In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report
por: Nagrani, Tarun, et al.
Publicado: (2010)

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke
por: Hilkens, Nina A., et al.
Publicado: (2018)

Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017)

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy
por: Sibbing, Dirk, et al.
Publicado: (2009)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Parfrey, Shane, et al.
Publicado: (2022)

Trends in antiplatelet strategies 12-months following coronary stent placement in anticoagulated patients
por: Gamvroulas, Eleni M., et al.
Publicado: (2023)

BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
por: Pan, ChangE, et al.
Publicado: (2012)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Tailored Antiplatelet Therapy in Patients Undergoing PCI: Is Rapid Bedside Genetic Testing the Answer?
por: Faxon, David P.
Publicado: (2020)

Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study
por: Na, Kun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8mmf3mg0lfs9lqs2ebker91q3